Stock Information

Symbol Market Last Change Volume

View Stock Information

Latest Webcast

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Latest Press Releases

  • Apr16

    Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance Read More

  • Apr02

    Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates Read More

  • Mar26

    Cancer Genetics to Host Fourth Quarter and Full Year 2017 Financial Results Read More

Latest Events

  • Apr02

    4th Quarter and Fiscal Year 2017 Conference Call
    Date: April 2, 2018

  • Nov09

    3rd Quarter 2017 Conference Call
    Date: November 9, 2017

  • Aug22

    Investor and Analyst Call
    Date: August 22, 2017


Cancer Genetics, Inc.
201 Route 17 North
2nd Floor
Rutherford, NJ 07070

Investor Relations

Discover Cancer Genetics Incorporated »

Our Research
With unparalleled excellence in oncology, our team is dedicated to empowering personalized cancer treatment.
Our Media
Stay current with the latest company news, articles, videos, and webinars.
Our Partners
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers in the U.S. and abroad.
Click here to login and view your reports.